Drug intelligence / Profile preview

SJP-304 + SJP-223

Development stage: Unknown
Lead developer: Stewart-Jackson Pharmacal
Modality: Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

SJP-304 + SJP-223 is a combination drug product developed for the prevention of veisalgia (commonly known as hangover). The combination aims to reduce or prevent common symptoms associated with veisalgia. While specific detailed mechanisms of action are not fully described in available data, the components likely include agents targeting symptoms such as nausea, headache, and other hangover-related effects. The development includes clinical trials assessing safety and efficacy for this indication.

Other names: SJP-304 + SJP-223

Beyond the preview

Go deeper on SJP-304 + SJP-223.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SJP-304 + SJP-223.

Explore the full profile